Year 5, N°17, September, 2002
Special Issue: World Congress of Nuclear Medicine

Abstracts

Article Nº AJ17-10

10. ONCOLOGY DIAGNOSIS
H.M. Abdel-Dayem
10.01

99MTC RH-ANNEXIN V FOR IMAGING APOPTOTIC CELLS: CLINICAL EXPERIENCE

 
C.R. Aguilar
10.02

LYMPHOSCINTIGRAPHY WITH 99MTC-DEXTRAN AND RADIOGUIDED BIOPSY IN SENTINEL NODE LOCALIZATION IN BREAST CANCER

 
C.R. Aguilar Ramirez
10.03

99M TC -DEXTRAN LYMPHOSCINTIGRAPHY AND RADIO GUIDED BIOPSY FOR LOCALIZING THE SENTINEL NODE IN MALIGNANT MELANOMA

 
O. Alonso
10.04

COMPARISON OF 99MTC-MIBI SCANNING AND SENTINEL NODE BIOPSY IN THE DETECTION OF OCCULT MELANOMA LYMPH NODE METASTASES

 
O. Alonso
10.05

REGIONAL LYMPH NODE STAGING IN MELANOMA PATIENTS BY MEANS OF 99MTC-MIBI SCINTIGRAPHY

 
O. Alonso
10.06

LYMPHATIC MAPPING AND SENTINEL NODE IDENTIFICATION IN PATIENTS WITH CERVIX CANCER UNDERGOING RADICAL HYSTERECTOMY

 
G. Ascoli
10.07

A VERY ACCURATE METHOD FOR SENTINEL LYMPH NODE INVESTIGATION: GAMMA DETECTING PROBE ASSICIATED WITH SPECT EXAMINATION FOR DEPTH

 
G.P. Bandopadhyaya
10.08

OCULAR MELANOMA IMAGING WITH 99M TC (V)DIMERCAPTO SUCCINIC ACID IN THYROTOXIC (GRAVE'S) PATIENTS PRETREATED WITH RADIOIODINE

 
H. Barthel
10.09

[18F]FLUOROETANIDAZOLE FOR IMAGING MODULATED TUMOUR HYPOXIA WITH POSITRON EMISSION TOMOGRAPHY (PET)

 
R.P. Baum
10.10

PROGNOSTIC FACTORS FOR CARCINOMA OF UNKOWN PRIMARY LOCALIZED TO THE NECK ONLY (CUP SYNDROME) AND THE ROLE OF F-18-FDG PET FOR DIAGNOSIS AND THERAPEUTIC MANAGEMENT

 
T.M. Behr
10.11

CHOLECYSTOKININ(CCK)-B/GASTRIN-RECEPTOR BINDING PEPTIDES FOR DIAGNOSIS AND THERAPY OF METASTATIC MEDULLARY THYROID CANCER (MTC)

 
T.M. Behr
10.12

DOES EXTERNAL SCINTIGRAPHY ALLOW FOR PREDICTIONS WITH RESPECT TO THE TOXICITY AND THERAPEUTIC EFFICACY OF HERCEPTIN® THERAPY OF HER2/NEU EXPRESSING BREAST CANCER ?

 
H.B. Bihl
10.13

COMPLEMENTARY ROLE OF 3'-DEOXY-3'-[F-18] FLUOROTHYMIDINE (FLT) AND F-18-FDG PET IMAGING IN ONCOLOGY

 
S.E. Bouyoucef
10.14

INFLUENCE OF THE DEPTH AND THE SITE OF THE NIDUS IN INTRAOPERATIVE LOCALISATION OF OSTEOID OSTEOMA

 
W. Cao
10.15

A COMPARATIVE STUDY OF 99MTC-HL91 AND 99MTC-MIBI IMAGING IN EXPERIMENTAL TUMOR AND INFLAMMATORY MODELS

 
J. Chen
10.16

USING 99TCM-MIBI MAMMOSCINTIGRAPHY TO DIFFERENTIATE NODULAR LESIONS OF BREAST AND DETECT AXILLARY LYMPH NODE METASTASES FROM BREAST CANCER

 
S.L. Chen
10.17

A SELF-CONTROL STUDY OF THREE RADIOPHARMACEUTICALS FOR LOCATING SENTINEL LYMPH NODE

 
S.L. Chen
10.18

LYMPHATIC MAPPING AND SENTINEL LYMPH NODE DETECTIONIN PATIENTS WITH BREAST CANCER

 
A. Collazo
10.19

DETECTION OF THE CUTANEOUS MELANOMAS, THEIR METASTASIS AND RELAPSES BY SCINTIGRAPHIES WITH 99MTC-HMPAO.

 
L.F. Colmenter
10.20

ROLE OF TC-99M-METHOXYISOBUTYLISONITRILE SCINTIMAMMOGRAPHY COMPARED TO MAMMOGRAPHY IN THE DETECTION OF BREAST CANCER IN VENEZUELAN WOMEN

 
R. Czepczynski
10.21

EVALUATION OF THE LYMPHATIC DRAINAGE OF THE THYROID TUMORS USING LYMPHOSCINTIGRAPHY

 
S.D. Dadparvar
10.22

EFFICACY OF 18FDG PET STUDY IN DETECTION OF COLON CARCINOMA

 
A. Dimitrakopoulou-Strauss
10.23

QUANTITATIVE DYNAMIC PET FDG STUDIES FOR THE DIFFERENTIATION OF BONE LESIONS

 
A. Dimitrakopoulou-Strauss
10.24

PROGNOSTIC ASPECTS OF FDG PET IN PATIENTS WITH METASTATIC COLORECTAL CANCER

 

A. Dimitrakopoulou-Strauss

10.25

COMPARISON OF QUANTITATIVE PET AND CYCLIN-A EXPRESSION

 
E.I. Escobar
10.26

COMPARISON BETWEEN NON-DEDICATED POSITRON EMISSION TOMOGRAPHY (NPET)WITH [F18] FLUOR DEOXI GLUCOSE (FDG)AND RADIONUCLIDE-LABELED SOMATOSTATIN ANALOGUES FOR THE DIAGNOSTIC PURPOSES IN THE DIFFERENTIAL THYROID CANCER

 
E.I. Escobar
10.27

RETROSPECTIVE ANALYSIS OF SENSIBILITY AND IMPACT OF NON-DEDICATED POSITRON EMISSION TOMOGRAPHY (NPET) IN THE MANAGEMENT OF PATIENTS WITH CANCER

 
S. Fatima
10.28

TO ASSESS THE DIAGNOSTIC ACCURACY OF 99M-TC-MIBI PLANAR & SPECT IMAGING IN DIFFERENTIATING SCAR TISSUE FROM RECURRENCE OF BREAST CARCINOMA AFTER SURGERY

 
S.F. Grant
10.29

EFFECTS OF TC-99M SULFUR COLLOID FILTRATION ON AXILLARY SENTINEL NODE VISUALIZATION DURING PREOPERATIVE BREAST LYMPHOSCINTIGRAPHY

 
M.R. Griffiths
10.30

COMBINING FUNCTIONAL CT AND FDG PET ALLOWS THE CALCULATION OF FDG EXTRACTION FRACTION AND HEPATIC GLUCOSE PHOSPHORYLATION

 
J. Grimm
10.31

RADIO-GUIDED SURGERY IN VULVAR CANCER- FIRST EXPERIENCES

 
J. Grimm
10.32

RADIO-GUIDED SURGERY IN CERVICAL CANCER- FIRST EXPERIENCES

 
Y.H. Guan
10.33

FDG PET IN THE DIAGNOSIS OF MENINGEAL CARCINOMATOSIS

 
M.A. Guirao
10.34

STANDARDIZED UPTAKE VALUE OF FDG CORRECTED BY LEAN BODY MASS MEASURED BY DEXA

 
Z.H.Q. Huiqing
10.35

MAMMOGRAPHY AND SCINTIMAMMOGRAPHY IN DIAGNOSIS OF BREAST CANCER

 
H.J. Jacobsson
10.36

99TCM-HMPAO UPTAKE IN BREAST CANCER

 
H.J. Jacobsson
10.37

EARLY ASSESSMENT OF NEOADJUVANT CHEMOTHERAPY BY FEC-COURSES OF LOCALLY ADVANCED BREAST CANCER USING 99TCM-MIBI (SESTAMIBI) AND SPECT

 
S. Jana
10.38

SENTINEL NODE LOCALIZATION IN BREAST CANCER: EVALUATION OF CONTROVERSIES

 
K.J.A. Kairemo
10.39

RADIOLABELLED PHAGE DISPLAY PEPTIDE DERIVATIVES INHIBITING MATRIX METALLOPROTEINASES TARGET XENOGRAFTED TUMORS IN MICE

 
R. Kashyap
10.40

DIAGNOSTIC UTILITY OF RADIONUCLIDE PERFUSION SCAN AND IMMUNOCYTOLOGY IN EVALUATION OF SOLITARY THYROID NODULES

 
E.E. Kim
10.41

IMAGING CELLULAR TARGETS IN ONCOLOGY

 
A. Krol
10.42

COMPARATIVE BREAST PHANTOM STUDIES OF TOMOGRAPHIC SCINTIMAMMOGRAPHY PERFORMED WITH PET AND SPECT

 
L. Lamki
10.43

UNUSUAL CARDIOVASCULAR FINDINGS ON TOTAL-BODY F-18-FDG PET SCANS IN ONCOLOGY PATIENTS

 
L.M. Lamki
10.44

ACQUIRING ADDITIONAL DELAYED PET IMAGES IMPROVES SENSITIVITY AND SPECIFICITY IN ONCOLOGY CASES

 
F. Lomena
10.45

WHOLE-BODY FDG-POSITRON EMISSION TOMOGRAPHY IN BONE METASTASES. COMPARISON WITH BONE SCINTIGRAPHY.

 
A. Marwah
10.46

EFFECT OF THE BREAST LESION SIZE AND PATIENT AGE ON OUTCOME OF RESULTS OF SCINTIMAMMOGRAPHY IN INDIAN WOMEN: A HEAD TO HEAD COMPARISON OF TC-99M TETROFOSMIN (TF) AND TC-99M METHYLENE DIPHOSPHONATE (MDP) SCINTIMAMMOGRAPHY (SMM)

 
T. Massardo
10.47

DIAGNOSTIC VALUE OF EARLY 99M-TC METILENDIPHOSPHONATE SCINTIMAMMOGRAPHY IN THE ASSESSMENT OF PALPABLE BREAST TUMORS

 
T. Massardo
10.48

DIAGNOSTIC VALUE OF 99M-TC GLUCOHEPTONATE SCINTIMAMMOGRAPHY IN THE ASSESSMENT OF PALPABLE BREAST TUMORS

 
S. Maza
10.49

SIGNIFICANCE OF THE SPEED OF LYMPHATIC DRAINAGE FOR METASTATIC SPREAD OF CUTANEOUS MALIGNANT MELANOMA

 
T.R. Miller
10.50

CARBON-11 ACETATE PET IN RECURRENT PROSTATE CANCER

 
J.S. Moller
10.51

LOCALISATION OF SENTINEL LYMPH NODES: WILL IT INFLUENCE THE MANAGEMENT OF PENIS CARCINOMA?

 
A. Mudun
10.52

COMPARISON OF SUBDERMAL AND PERITUMORAL INJECTION TECHNIQUES OF LYMPHOSCINTIGRAPHY TO DETERMINE THE SENTINEL LYMPH NODE IN BREAST CANCER

 
E.C. Noguera
10.53

99MTC SOMATOSTATING IMAGING FOR DETECTION OF SOMATOSTATING RECEPTOR.A PRELIMINARY RESULTS

 
P. Predic
10.54

DIAGNOSIS BRAIN TUMORS WITH TC-99M-MIBI AND FOLOW-UP SURROUNDING OEDEMA AFTER AND POST OEDEMA THERAPY WITH TC-99M-ECD

 
G.M. Qin
10.55

TECHNETIUM-99M LABELED ANTISENSE OLIGONUCLEOTIDE-NONINVASIVE TUMOR IMAGING IN MICE

 
R. Santa Cruz
10.56

EVALUATION OF TC-99M SESTAMIBI SCINTIMAMMOGRAPHY IN THE DIAGNOSIS OF BREAST CANCER PATIENTS

 
G.W. Sloof
10.57

FEASIBILITY OF LYMPHOSCINTIGRAPHY OF THE GASTRIC CARDIA

 
G.S. Spana
10.58

MAPPING LYMPHATIC NODES: ROLE OF THROMBOSPONDIN

 
L.G. Strauss
10.59

VEGF EXPRESSION AND FDG KINETICS

 
L.G. Strauss
10.60

COMPARISON OF DYNAMIC FDG PET AND GENE CHIP DATA

 
J.N. Talbot
10.61

FIVE YEAR EXPERIENCE IN THE DETECTION OF RECURRENCE OF OVARIAN CANCER WITH [F18]-FDG USING AN HYBRID (CDET) GAMMA CAMERA

 
L.A. Torres
10.62

PHASE I CLINICAL TRIAL OF THE HUMANIZED ANTI-EGF-R ANTIBODY H-R3 LABELED WITH 99MTC IN PATIENTS WITH TUMOR OF EPITHELIAL ORIGIN

 
M. Uchiyama
10.63

INCREASED UPTAKE IN THE END OF LONG BONES ON BONE SCAN IN MULTIPLE MYELOMA

 
R.A. Valdés Olmos
10.64

FEASIBILITY OF TC-99M BRU 59-21 IN ASSESSING TUMOR HYPOXIA IN HEAD AND NECK CANCER

 
R.A. Valdés Olmos
10.65

REPRODUCIBILITY OF SENTINEL NODE LYMPHOSCINTIGRAPHY IN BREAST CANCER

 
L.I. Wiebe
10.66

NOVEL RADIOLABELLED PYRIMIDINE NUCLEOSIDE MIMICS FOR SCINTIGRAPHIC ASSESSMENT OF TISSUE PROLIFERATION

 
H. Wu
10.67

USING 99MTC-MIBI TO EVALUATE THE EFFECTS OF CHEMOSENSITIZER ON P-GLYCOPROTEIN IN MULTIDRUG-RESISTANT CARCINOMA CELLS

 
J.S. Xia
10.68

99MTC-HYNIC-TNF ANALOGUES (WH701) DERIVED FROM PHAGE DISPLAY PEPTIDE LIBRARIES FOR IMAGING TNF -RECEPTOR-POSITIVE OVARIAN CARCINOMA: PRECLINICAL EVALUATION

 
Z. Zhang
10.69

USING 99MTC-MIBI TO EVALUATE THE EFFECTS OF CHEMOSENSITIZER ON P-GLYCOPROTEIN IN MULTIDRUG-RESISTANT CARCINOMA CELLS

 
J. Zhao
10.70

VALUE OF 18F-FDG POSITRON EMISSION TOMOGRAPHY IN CLINICAL STAGING AND FOLLOW-UP OF GASTRIC CARCINOMA

Cardiovascular |Cost Benefits|Endocrinology |Gastroenterology |Hematology |Infection| Musculoskeletal |Nephro-Urology |Neuro-Psychiatric Disorders |Oncology Diagnosis |Oncology Therapy |Pediatrics|Physics |Pulmonary |Radiopharmacy |Technology

 

 

Sitio desarrollado por SISIB - Universidad de Chile